Categories: All Articles • Nanoparticles • Dechelation • Cellular + Mito Dysfunction • GDD/Toxicity • Fibrosis • Other Disease • Chemistry • Heavy Metal Toxicity • Treatment Options • Water Contamination • Other Gd Uses • Pediatrics • Chelators

Bridget Belo 8/11/24 Bridget Belo 8/11/24

The Safety of Magnetic Resonance Imaging Contrast Agents (Aug 2024).

Kate 7/1/24 Kate 7/1/24

Deposition of Gadolinium in the Central and Peripheral Nervous Systems and Its Effects on Sensory, Cognitive, and Athletic Implications after Injections of GBCAs in Rats (2024).

Bridget Belo 4/1/24 Bridget Belo 4/1/24

Toxicity Mechanisms of Gadolinium and Gadolinium-Based Contrast Agents—A Review (2024).

Bridget Belo 12/25/23 Bridget Belo 12/25/23

Gadolinium Effects on Liposome Fluidity and Size Depend on the Headgroup and Side Chain Structure of Key Mammalian Brain Lipids (Dec 2023).

Bridget Belo 8/15/23 Bridget Belo 8/15/23

Uptake of Gadolinium-Based Contrast Agents by Blood Cells During Contrast-Enhanced MRI Examination

Kate 8/1/23 Kate 8/1/23

Gadolinium Deposition Disease Current State of Knowledge and Expert Opinion (2023).

Bridget Belo 7/4/23 Bridget Belo 7/4/23

Gadolinium contrast agents- challenges and opportunities of a multidisciplinary approach: Literature review (July 2023).

Bridget Belo 2/4/23 Bridget Belo 2/4/23

The onset of rare earth metallosis begins with renal gadolinium-rich nanoparticles from magnetic resonance imaging contrast agent exposure (2023).

Bridget Belo 1/11/23 Bridget Belo 1/11/23

Altered Functional Mitochondrial Protein Levels in Plasma Neuron-Derived Extracellular Vesicles of Patients With Gadolinium Deposition (2022).

Kate 10/1/22 Kate 10/1/22

Commentary on the Association of Symptoms Associated With Gadolinium Exposure/Gadolinium Deposition Disease and Gadolinium-Based Contrast Agents (2022).

Bridget Belo 5/31/22 Bridget Belo 5/31/22

Low-Dose Naltrexone and Pain Relief in Gadolinium Deposition Disease: A Case Series

Kate 2/1/22 Kate 2/1/22

Symptoms Associated with Gadolinium Exposure (SAGE): A Suggested Term (2022).

Kate 1/1/22 Kate 1/1/22

Dynamic Serial Cytokine Measurements During Intravenous Ca-DTPA Chelation in Gadolinium Deposition Disease and Gadolinium Storage Condition: A Pilot Study (2022).

Bridget Belo 12/7/20 Bridget Belo 12/7/20

Benefits and Detriments of Gadolinium from Medical Advances to Health and Ecological Risks (Dec 2020).

Kate 10/1/20 Kate 10/1/20

An initial investigation of serum cytokine levels in patients with gadolinium retention (2020).

Kate 8/1/20 Kate 8/1/20

Is Small Fiber Neuropathy Induced by Gadolinium-Based Contrast Agents? (2020).

Bridget Belo 3/13/18 Bridget Belo 3/13/18

Evaluating the potential of chelation therapy to prevent and treat gadolinium deposition from MRI contrast agents (Mar 2018).

Bridget Belo 12/7/13 Bridget Belo 12/7/13

High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material (2014).

Submit any resources that should be included on the site.

Explore Gadolinium 64

This site is also accessible via contrastdie.com

Fair Use Disclaimer
This website features copyrighted material used in accordance with the principles of fair use as outlined in Section 107 of the U.S. Copyright Act. The material is provided to inform, educate, and encourage public discussion on important issues, including health, education, and science. All content is shared with the intent of advancing understanding and fostering meaningful dialogue. This use is non-commercial and aligns with fair use standards for purposes such as research, education, and commentary. If you believe any content on this site infringes on your copyright, please contact us at Contact Us and we will review your concerns promptly.